Like all of the TNF inhibitors, infliximab is an expensive medication, costing about US$1650 for a 100 mg dose, and is covered by almost every medical insurance plan (though caps on many plans make it possible to be covered for only a subset of treatments in the course of a year). Infliximab is supplied as a sterile, white, lyophilized (freeze dried) powder and must be reconstituted and administered by a health care professional, usually in a hospital or office setting. For this reason it is usually covered under major medical insurance rather than prescription drug coverage.
According to the labeling, the current dosing is:
The loading regimen for all approved indications occurs at weeks 0, 2, and 6 at the above dosages.
Infliximab is available from the NHS in the UK for Crohns treatment provided three criteria are met. Patients should have severe active Crohn's disease with a CDAI score of 300 or more, have not responded to immunomodulating drugs and corticosteroids, and for whom surgery is inappropriate.
Further Reading
This article is licensed under the Creative Commons Attribution-ShareAlike License.
It uses material from the Wikipedia article on
"Infliximab"
All material adapted used from Wikipedia is available under the terms of the
Creative Commons Attribution-ShareAlike License.
Wikipedia® itself is a registered trademark of the Wikimedia Foundation, Inc.